Reauthorising US FDA user fees: a slow-moving train wreck?
This article was originally published in SRA
Executive Summary
Failure by Congress to secure the timely reauthorisation of critical drug and device user fee programmes will mean trouble for the Food and Drug Administration, industry and patients, warns Steven Grossman.